GTC and LFB collaborate on transgenically produced products
GTC Biotherapeutics and LFB Biotechnologies have entered into a collaboration, which focuses on recombinant plasma proteins and monoclonal antibodies (mAbs) to eventually develop a robust pipeline for treating conditions such as haemophilia.